ライフサイエンスコーパス: circulatory

1 le levels, working together to mediate these circulatory abnormalities.

2 for both normal cardiovascular function and circulatory adaptation to hypoxia.

3 nsporters, association with serum albumin in circulatory and extracellular spaces, and association wi

4 flammatory cytokines and attenuated systemic circulatory and febrile responses, likely reflecting dec

5 The close alignment of the circulatory and ingestion systems, as well as other morp

6 W]) at each speed, we were able to determine circulatory and respiratory costs.

7 rporeal membrane oxygenation (ECMO) provides circulatory and respiratory support for patients with se

8 y, we assessed the phenotype and function of circulatory and tissue-resident NK cells in a unique coh

9 Hypothermic circulatory arrest (HCA) provides neuroprotection during

10 Mean times to circulatory arrest and electrical asystole were 8 +/- 1

11 Times to circulatory arrest and electrical asystole were recorded

12 Circulatory arrest occurred 7.6+/-0.3 min following WLST

13 m withdrawal of life-supporting treatment to circulatory arrest was 150 minutes.

14 esumed to result from transient intracranial circulatory arrest.

15 ng periods of low cerebral blood flow and/or circulatory arrest.

16 RBCs to pass through the IES, the narrowest circulatory bottleneck in the spleen, our results offer

17 lar interleukins (IL-6, IL-1beta, TNFalpha), circulatory C-reactive protein (CRP), serum amyloid A (S

18 set of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are a

19 ed as a subset of sepsis in which underlying circulatory, cellular, and metabolic abnormalities are a

20 rogress to septic shock, defined by profound circulatory, cellular, and metabolic abnormalities, and

21 jected to 1 hour of warm ischemia time after circulatory cessation, then flushed with a CD47 monoclon

22 ardiographic predictors of HF were masked by circulatory changes in patients with cirrhosis.

23 r (2%) patients (one respiratory failure and circulatory collapse [possibly related to sunitinib], on

24 A type 1 presentation, defined as circulatory collapse, was found in 12/33 patients (36.4%

25 al failure, oesophageal varices haemorrhage, circulatory collapse, wound infection, ileus, cerebrovas

26 annel is associated with edema formation and circulatory collapse.

27 The two groups had similar risks of circulatory complications and second cancers.

28 halt disease progression but also to prevent circulatory compromise resulting from the mass effect on

29 cal treatment it is critical to maintain the circulatory concentration of drugs within their therapeu

30 as the underlying cause of death were other circulatory conditions (7566 [35%] of 21 677 deaths), sy

31 rimary neoplasms, cardiac disease, and other circulatory conditions accounted for 31%, 22%, and 15% o

32 ndicate new strategies for probing autonomic circulatory control and ultimately, susceptibility to hy

33 .15 W per each L min(-1) increase in VE, and circulatory costs were 0.24 +/- 0.05 W per each bpm incr

34 transplantation (LT) between donation after circulatory death (DCD) and donation after brain death (

35 We previously showed that donation after circulatory death (DCD) canine hearts can be resuscitate

36 Donation after circulatory death (DCD) donor pool remains underutilized

37 Donation after circulatory death (DCD) donors are an important source o

38 Most kidneys from potential elderly circulatory death (DCD) donors are declined.

39 Liver transplantation using donation after circulatory death (DCD) donors is associated with inferi

40 l New England Organ Bank (NEOB) donors after circulatory death (DCD) donors were analyzed between Jul

41 While donation after circulatory death (DCD) has expanded options for organ d

42 rsists despite a high rate of donation after circulatory death (DCD) in the Netherlands.

43 Donation after circulatory death (DCD) is current clinical practice to

44 The use of livers from donation after circulatory death (DCD) is increasing, but concerns exis

45 Organ donation after circulatory death (DCD) is increasingly being used as a

46 In the United Kingdom, donation after circulatory death (DCD) kidney transplant activity has i

47 Donation after circulatory death (DCD) kidney transplantation has accep

48 or recipients of single-organ donation after circulatory death (DCD) kidneys preserved with HMP with

49 en validated for appraisal of donation after circulatory death (DCD) kidneys.

50 The transplantation of donation after circulatory death (DCD) livers is limited by poor outcom

51 Hearts donated following circulatory death (DCD) may represent an additional sour

52 e United Kingdom's controlled donation after circulatory death (DCD) program and the controversies su

53 Donation after circulatory death (DCD) provides an alternative pathway

54 atients who attempted to donate organs after circulatory death (DCD) using a standardized DCD protoco

55 n after Brain Death (DBD) and Donation after Circulatory Death (DCD) were included.

56 (WI) lesions that occur with donation after circulatory death (DCD) would significantly increase the

57 ere procured, four (40%) from donation after circulatory death (DCD), of which nine were transplanted

58 in kidney grafts obtained from donors after circulatory death (DCD).

59 erly donors after brain death (DBD) or after circulatory death (DCD).

60 post-transplant biopsies from donation after circulatory death (DCD, n = 36, mean warm ischemia time

61 ignificantly reduced CIT were donation after circulatory death (P = 0.03), shorter transport time (P

62 ransplants from donations after uncontrolled circulatory death (uDCD).

63 Twelve livers (9 donation after circulatory death [DCD] and 3 from brain-dead donors), m

64 1, 2013, and April 30, 2015 (donation after circulatory death [DCD] donors).

65 ved the rate of mainly deceased donors after circulatory death and from older donors.

66 Four organs were recovered from donors after circulatory death and rejected due to prolonged donor wa

67 Livers retrieved after circulatory death are associated with an increased incid

68 Kidneys from a donation after circulatory death donor were transplanted into two nontr

69 ere from a 35-year-old man, a donation after circulatory death donor.

70 Thirty-six donation after circulatory death donors (28% of actual donors) were jud

71 A further 15 donation after circulatory death donors had brain death confirmed or ha

72 donors, with 314 (19.5%) from donation after circulatory death donors.

73 Donations after uncontrolled circulatory death grafts show more fibrosis after transp

74 .02) in recipients with older donation after circulatory death grafts.

75 Donation after circulatory death has been responsible for 75% of the in

76 Machine perfusates of 390 donations after circulatory death kidneys were analyzed for histone conc

77 ival in recipients with older donation after circulatory death kidneys.

78 n addition, 4 discarded human donation after circulatory death livers were subjected to ex vivo reper

79 These grafts from donation after circulatory death or expanded criteria donors are more s

80 gaps in the well-established donation after circulatory death process in Ontario.

81 ncern that the success of the donation after circulatory death program has been at the expense of don

82 The development of a national donation after circulatory death program has had minimal impact on the

83 o ascertain the impact of the donation after circulatory death program on donation after brain death

84 Donation after circulatory death recipients had comparable 1-year patie

85 Donation after circulatory death recipients were stratified according t

86 donation after brain death to donation after circulatory death substitution rate observed was 8%; how

87 9 of the 130 actual donors if donation after circulatory death was not available.

88 optimal liver from a 57-year-old donor after circulatory death who had been hospitalized for 9 days;

89 ex, height, type (donor after brain death or circulatory death), bilirubin, smoking history, and whet

90 ations after brain death, 13 donations after circulatory death), with a median (range) donor age of 6

91 al determination of death and donation after circulatory death, end-of-life care, performance metrics

92 ith nonwhite donor ethnicity, donation after circulatory death, transplantation after 2008, and trans

93 57 patients were assessed for donation after circulatory death.

94 ) were medically suitable for donation after circulatory death.

95 able to a notable increase in donation after circulatory death.

96 BD, 2 transitioned to actual donation after circulatory death.

97 ates that excluded ground-based monitors for circulatory deaths [RR = 1.02, 95% confidence interval (

98 Contractility, looping, and circulatory defects were evident, but larval mahi did no

99 l blood flow (CBF), and significant cerebral circulatory delay compared to controls.

100 laxation to match cardiac output to changing circulatory demands.

101 However, PEEP may also cause circulatory depression and contribute to ventilator-indu

102 Donation after circulatory determination of death (DCD) increased fourf

103 al practice of neonatal organ donation after circulatory determination of death (DCDD) remains uncomm

104 nt recipients receive a graft donation after circulatory determination of death (DCDD).

105 r 0.5 Gy there are increasing trends for all circulatory disease (n = 10,209; excess relative risk/Gy

106 e are negative mortality dose trends for all circulatory disease (p = 0.014) and ischaemic heart dise

107 red with regular meat eaters for deaths from circulatory disease [higher in fish eaters (HR: 1.22; 95

108 ell-known lifestyle/medical risk factors for circulatory disease implies that confounding of the dose

109 inverse association of coffee drinking with circulatory disease mortality (HR, 0.78 [CI, 0.68 to 0.9

110 relationship between influenza activity and circulatory disease mortality reported in temperate coun

111 No association with circulatory disease mortality was found.

112 The SMR for circulatory disease was increased at 2.72 (1.88-3.95; p<

113 h-dose ionising radiation is associated with circulatory disease.

114 th the general population, particularly from circulatory disease.

115 All circulatory-disease and ischaemic-heart-disease risk red

116 We evaluated risks of circulatory-disease mortality associated with <0.5 Gy ra

117 ier findings and strengthen the evidence for circulatory-disease mortality radiation risk at doses <0

118 s of YLDs, and level with cardiovascular and circulatory diseases in terms of DALYs.

119 types of cancer, total and specific types of circulatory diseases, and other causes were not elevated

120 These people are often diagnosed with other circulatory disorders or symptoms of circulatory disturb

121 deaths, and deaths due to external injuries, circulatory disorders, digestive disorders, and cancer (

122 Associations were most evident among circulatory disorders.

123 h other circulatory disorders or symptoms of circulatory disturbance.

124 Systemic circulatory dysfunction (SCD) was estimated by plasma re

125 blood clots, plays an important role in this circulatory dysfunction in AD.

126 sis and ascites have portal hypertension and circulatory dysfunction.

127 No practical tool quantitates the risk of circulatory-etiology death (CED) immediately after succe

128 y after resuscitation according to risk of a circulatory-etiology death.

129 n = 90) presenting with sepsis-induced acute circulatory failure and considered for volume expansion.

130 c shock currently refers to a state of acute circulatory failure associated with infection.

131 might participate in the pathophysiology of circulatory failure during sepsis, and represent a poten

132 responsiveness in ventilated patients with a circulatory failure of any cause.

133 Adult patients with acute circulatory failure, having continuous cardiac output mo

134 intubated patients with sepsis-related acute circulatory failure.

135 er dysfunction with vascular leakage-induced circulatory failure.

136 Derangement of circulatory flow affects many vital organs; without prop

137 of S1P gradients between lymphoid organs and circulatory fluids in homeostasis are increasingly well

138 The concentration of S1P is higher in circulatory fluids than in lymphoid organs, and the S1P1

139 penetrated into microtumors and remained non-circulatory for several days before undergoing vascular

140 The circulatory half-life (t1/2) was shown to be dependent o

141 -1 analogue demonstrated a promising gain in circulatory half-life and absorption time compared to it

142 the pharmacokinetics of drug carriers who's circulatory half-life is dependent in some manner upon i

143 We recently reported that the long circulatory half-life of FX is linked to its interaction

144 We utilize red blood cells to prolong the circulatory half-life of VHHs.

145 ty or a second antibody fragment to tune its circulatory half-life or its avidity.

146 ies of human serum albumin to tune the blood circulatory half-life, hepatic accumulation and gene sil

147 s, such as low tissue penetration and a long circulatory half-life.

148 ich endothelium function is critical for the circulatory homeostasis, but there are limited data on e

149 2; 95% confidence interval [CI], 1.01-1.04), circulatory (HR, 1.03; 95% CI, 1.01-1.05), and respirato

150 the skin, lung, and intestine and increased circulatory IL-6 and G-CSF, along with a hematopoietic s

151 urological injury remains challenging due to circulatory immune clearance.

152 Circulatory immune mediators profiles were then characte

153 with cardioprotective effects, modulation of circulatory inflammation and extended survival.

154 loped a microfluidic approach to establish a circulatory microenvironment and studied circulating hum

155 trated that with age, the composition of the circulatory milieu changes in ways that broadly inhibit

156 isks (RRs) for the association of PM2.5 with circulatory mortality and ischemic heart disease.

157 nt O3 contributes to risk of respiratory and circulatory mortality.

158 mon causes of death included diseases of the circulatory (n = 247 [46.9%]) and respiratory systems (n

159 nosuppressants, plays important roles in the circulatory, nervous, and immune systems.

160 plexi that undergo vascular remodeling into circulatory networks, requiring coordinated growth inhib

161 3 distinct neutrophil subsets: resting/naive circulatory neutrophils, parainflammatory neutrophils fo

162 le cell disease is caused by vaso-occlusion: circulatory obstruction leading to tissue ischemia and i

163 f rhythmic hand grip exercise, post exercise circulatory occlusion (PECO) was applied to the resting

164 0.51 l min(-1) in patients until release of circulatory occlusion, with no significant difference in

165 e constructs that are integrated in a closed circulatory perfusion system, facilitating inter-organ r

166 arkers, including lipoproteins, blood sugar, circulatory pressure, proinflammatory markers, kidney fu

167 Type 1 diabetes is known to cause circulatory problems in the eyes, heart, and limbs, and

168 y life-threatening airway, breathing, and/or circulatory problems; and usually associated with skin a

169 ater stages of infection, WT mice had higher circulatory proinflammatory cytokines and lower anti-inf

170 Although we recognize that Fontan circulatory properties are associated with extracardiac

171 Examination of the cerebral circulatory responses to acute exercise in the elderly m

172 The tool may allow for estimation of circulatory risk and improve the triage of survivors of

173 Thus, circulatory S1P confinement could be a primordial strate

174 Circulatory S1P has critical roles in maturation and hom

175 study provides a new insight to the roles of circulatory shear stress in cellular responses of circul

176 Circulatory shock induces the loss of energy-dependent v

177 thought to contribute to the development of circulatory shock seen in fatal EBOV infections.

178 ing vascular resistance during recovery from circulatory shock.

179 work overload associated with a hyperdynamic circulatory state.

180 lder wasps in glycerolipids, amino acids and circulatory sugars.

181 tion (72, 0.6%), unplanned use of mechanical circulatory support (64, 0.5%), and major dissection (41

182 whom 55 required inotropes and/or mechanical circulatory support (FM) and the remaining 132 were hemo

183 teragency Registry for Mechanically Assisted Circulatory Support (INTERMACS).

184 teragency Registry for Mechanically Assisted Circulatory Support (INTERMACS).

185 f infection and its prevention in mechanical circulatory support (MCS) device recipients.

186 ing number of devices can provide mechanical circulatory support (MCS) to patients with acute hemodyn

187 s ICM 4%; P<0.001), biventricular mechanical circulatory support (myocarditis 19% versus NICM 2%, ver

188 A temporary mechanical circulatory support (n = 30) was instituted in 16.8% of

189 ermine whether a new percutaneous mechanical circulatory support (pMCS) device (Impella CP, Abiomed,

190 s unknown whether newer-generation temporary circulatory support (TCS) devices afford children a mean

191 Mechanical circulatory support after HTx does not prevent LA.

192 equiring mechanical ventilation, vasopressor circulatory support and intermittent hemodialysis.

193 nation offers the advantage of biventricular circulatory support and oxygenation, but there are signi

194 ed while on assisted ventilation, mechanical circulatory support and with renal dysfunction.

195 toring hemodynamic stability with mechanical circulatory support before HTx should mitigate this prob

196 teragency Registry for Mechanically Assisted Circulatory Support class, use of multiple inotropes, se

197 Short-term mechanical circulatory support devices acutely improve hemodynamic

198 To review temporary percutaneous mechanical circulatory support devices for the treatment of cardiog

199 ussed and the clinical utility of mechanical circulatory support devices is reviewed, as are the Amer

200 eviously or actively supported by mechanical circulatory support devices remains poorly described in

201 Now, several percutaneous mechanical circulatory support devices, including Impella (Abiomed,

202 the utility of existing RV acute mechanical circulatory support devices.

203 modynamic effects of percutaneous mechanical circulatory support devices.

204 ging patients with a percutaneous mechanical circulatory support devices.

205 ng to percutaneous left and right mechanical circulatory support devices.

206 n 11 patients; 3 patients were on mechanical circulatory support for severe heart failure.

207 alyses may be less critical after mechanical circulatory support implant, when there are likely fewer

208 bing experience with percutaneous mechanical circulatory support in cardiogenic shock.

209 uded pretransplant support (25.6% mechanical circulatory support in nonsevere vs. 44.9% severe LA), h

210 A-ECMO) is increasingly used as a short-term circulatory support in patients with refractory cardioge

211 e standard of care for short-term mechanical circulatory support in pediatrics.

212 Extracorporeal circulatory support is a life-saving technique, and its

213 ysis (LLH) during continuous-flow mechanical circulatory support is associated with subsequent thromb

214 and experience with percutaneous mechanical circulatory support may offer the prospect of better out

215 RV acute mechanical circulatory support now represents an important step in

216 ce, 44% received or were awaiting mechanical circulatory support or transplant for end-stage heart fa

217 k providing a bridge to long-term mechanical circulatory support or transplantation.

218 teragency registry for mechanically assisted circulatory support patient profiles 1 and 2, the need f

219 teragency Registry for Mechanically Assisted Circulatory Support profile 4 (65% LVAD vs. 34% OMM; p <

220 s, percutaneously delivered acute mechanical circulatory support pumps specifically designed to suppo

221 rome diagnosis and treatment, extracorporeal circulatory support setting, outcome definitions, and ev

222 tion left ventricular assist devices provide circulatory support that is minimally or entirely nonpul

223 Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) compares t

224 tand the physiological effects of mechanical circulatory support therapy.

225 yndrome patients treated with extracorporeal circulatory support was performed.

226 No mechanical circulatory support was used in 41 286 (54%) patients, 2

227 teragency Registry for Mechanically Assisted Circulatory Support who underwent LVAD implantation betw

228 teragency Registry for Mechanically Assisted Circulatory Support who underwent primary continuous-flo

229 orporeal membrane oxygenation and mechanical circulatory support with a left ventricular assist devic

230 Mechanical circulatory support with a left ventricular assist devic

231 teragency Registry for Mechanically Assisted Circulatory Support) national registry, poor outcome was

232 teragency Registry for Mechanically Assisted Circulatory Support) profiles provide important prognost

233 teragency Registry for Mechanically Assisted Circulatory Support) registry who underwent VAD placemen

234 ropean Registry for Patients with Mechanical Circulatory Support) was used to identify adult patients

235 teragency Registry for Mechanically Assisted Circulatory Support), we sought to identify factors asso

236 assess change in metabolites with mechanical circulatory support, 41 patients with end-stage HF who u

237 he clinical progression, need for mechanical circulatory support, and outcomes of orthotopic heart tr

238 temporary best medical, surgical, mechanical circulatory support, and palliative care practices; advo

239 VADs) were developed as a means of temporary circulatory support, but the mechanical unloading they o

240 as receiving short- or long-term right-sided circulatory support, continuous inotropic support for >/

241 : cardiogenic shock, percutaneous mechanical circulatory support, extracorporeal membrane oxygenation

242 , renal disease, ventilatory support, use of circulatory support, glycoprotein inhibitor use, and ste

243 ated heart failure, initiation of mechanical circulatory support, heart transplant, or death.

244 heart transplantation and durable mechanical circulatory support, may be required in high-risk patien

245 Short-term mechanical circulatory support, natriuretic peptide decile, glomeru

246 ached the combined primary end point (death, circulatory support, or transplant) and 120 reached the

247 teragency Registry for Mechanically Assisted Circulatory Support-defined morbidity events.

248 The event rates of extracorporeal circulatory support-related complications were acute ren

249 Secondary outcomes were extracorporeal circulatory support-related complications, causes of dea

250 ced HF at centers that also offer mechanical circulatory support.

251 ly but require more biventricular mechanical circulatory support.

252 A-ECMO than to those on long-term mechanical circulatory support.

253 yndrome patients treated with extracorporeal circulatory support.

254 mes and decreased after long-term mechanical circulatory support.

255 s pacemakers, defibrillators, and mechanical circulatory support.

256 d to optimize and standardize extracorporeal circulatory support.

257 yndrome patients treated with extracorporeal circulatory support.

258 use of advanced therapies such as mechanical circulatory support.

259 l increase in use of percutaneous mechanical circulatory support.

260 t failure in tetralogy of Fallot, mechanical circulatory support/transplantation, sudden cardiac deat

261 autoimmune hemolytic anemia and cold-induced circulatory symptoms.

262 of the nervous system (1.37 [1.20-1.57]) or circulatory system (1.20 [1.00-1.43]); and admission to

263 ses of digestive organs, and diseases of the circulatory system (18%, 15%, and 14% of total AER, resp

264 0.81; 95% CI, 0.65-1.03) and other heart or circulatory system abnormalities (aRR, 0.98; 95% CI, 0.8

265 f tumoural cells in the mammary duct, in the circulatory system and in the bone.

266 Vessels of the lymphatic circulatory system are also subjected to fluid flow-asso

267 The mammalian circulatory system comprises both the cardiovascular sys

268 The human circulatory system consists of arterial blood that deliv

269 Deaths by diseases of the circulatory system declined more slowly after the onset

270 ks of obesity, type 2 diabetes mellitus, and circulatory system diseases.

271 ls, maintaining the dynamic equilibrium in a circulatory system driven by two pumps in series.

272 estimates of mortality from diseases of the circulatory system for PM2.5 modeled from RS with that f

273 The cholesterol transport across the circulatory system is a well-known process in contrast t

274 ls (CTCs) are rare tumour cells found in the circulatory system of certain cancer patients.

275 re likely than whites to be hospitalized for circulatory system or endocrine, nutritional, and metabo

276 er organisms rely on a closed cardiovascular circulatory system with blood vessels supplying vital nu

277 trast to animals, plants are sessile, lack a circulatory system, and have additional cellular structu

278 t in vivo, functionally couple to the host's circulatory system, and produce urine-like metabolites v

279 Upon development of a pumped circulatory system, C3 was synthesized in large amounts

280 elease of proinflammatory molecules into the circulatory system, is a major risk factor for severe il

281 Within the circulatory system, platelets guard circulating tumor ce

282 Vertebrates are endowed with a closed circulatory system, the evolution of which required nove

283 ense mechanism and suddenly spreads into the circulatory system, triggering a vigorous, self-injuriou

284 ow molecular weight compounds present in the circulatory system, which often serve as biomarkers in c

285 e gastrointestinal tract potentially via the circulatory system.

286 rians, for example an anus, nephridia, and a circulatory system.

287 o, forming a functional human-mouse chimeric circulatory system.

288 blood hemostasis and maintenance of a closed circulatory system.

289 nd S1P is spatially compartmentalized in the circulatory system.

290 ther exogenous components, into the female's circulatory system.

291 significance as a key feature of the closed circulatory system.

292 f vertebrates in the development of a closed circulatory system.

293 dapted to the barriers imposed by the closed circulatory system.

294 r measurements when emplaced directly in the circulatory systems of living animals.

295 using heterochronic parabiosis, in which the circulatory systems of young and old animals are joined,

296 ks is the key process for the development of circulatory systems.

297 biquitous in animal locomotion, feeding, and circulatory systems.

298 ings can reduce immune clearance and prolong circulatory times, thereby enhancing therapeutic capacit

299 of glycoproteins, DNA biomarkers, micro-RNA, circulatory tumor cells (CTC) and some potential biomark

300 nutrients reveal that, on a molar basis, the circulatory turnover flux of lactate is the highest of a